Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Inflammatory Demyelinating Polyneuropathy Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Homewood, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Interferon Beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2010 · Synced May 21, 2026, 6:56 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 6:56 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Gamunex-C, Xembify
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 6:56 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced May 21, 2026, 6:56 PM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Neuropathy
Interventions
Alemtuzumab infusion
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced May 21, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Scottsdale, Arizona • Carlsbad, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced May 21, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced May 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Augusta, Georgia • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Rancho Mirage, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Empasiprubart IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
Rancho Mirage, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:56 PM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-881, HYQVIA, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions
KITE-363, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 6:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 21, 2026, 6:56 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
H.P. Acthar® Gel
Drug
Lead sponsor
Mamatha Pasnoor, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced May 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
SAR445088 (IV), SAR445088 (SC)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced May 21, 2026, 6:56 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
Interventions
Not listed
Lead sponsor
Charles M Knudson
Other
Eligibility
12 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Intravenous immune globulin G, Subcutaneous immune globulin G
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Imeroprubart, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
31
States / cities
Tucson, Arizona • Carlsbad, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:56 PM EDT